Live Breaking News & Updates on California Company Profile

Stay updated with breaking news from California company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $2.00 at Barclays

Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $2.00 at Barclays
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United States , Davidw Meline , Zurcher Kantonalbank Zurich Cantonalbank , Pacific Biosciences , Oene Mark Van , Advisor Group , California Inc , Goldman Sachs Group , China Universal Asset Management Co , Interchange Capital Partners , California Company Profile , Jpmorgan Chase Co , Free Report , California Price , Get Free Report , Director David , Funds Weigh In On Pacific Biosciences , Capital Partners , Financial Markets , Universal Asset Management , Kantonalbank Zurich Cantonalbank , California Company , California Daily ,

Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.3%

Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.3%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Zurcher Kantonalbank Zurich Cantonalbank , Sanfordc Bernstein , Pacific Biosciences , Oene Mark Van , Davidw Meline , Securities Exchange Commission , Advisor Group , California Company Profile , China Universal Asset Management Co , California Inc , Goldman Sachs Group , Interchange Capital Partners , Jpmorgan Chase Co , Get Free Report , California Stock Down , Exchange Commission , Director David , Funds Weigh In On Pacific Biosciences , Capital Partners , Financial Markets , Universal Asset Management , Kantonalbank Zurich Cantonalbank , California Company , California Daily ,

Pacific Biosciences of California (NASDAQ:PACB) Trading Up 10.1%

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) were up 10.1% on Monday . The company traded as high as $2.03 and last traded at $2.02. Approximately 5,116,811 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 9,845,091 shares. The stock had previously closed […] ....

United States , Oene Mark Van , Davidw Meline , Pacific Biosciences , Goldman Sachs Group , California Company Profile , California Inc , Qube Research Technologies Ltd , Moody Aldrich Partners , Jpmorgan Chase Co , Investment Management , Securities Exchange Commission , Get Free Report , California Price , Exchange Commission , Director David , Aldrich Partners , Technologies Ltd , California Company , California Daily , Pacific Biosciences Of California , Nasdaq Pacb ,

Sanford C. Bernstein Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $2.50

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price reduced by Sanford C. Bernstein from $9.00 to $2.50 in a report released on Thursday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other research firms have also weighed in on PACB. Scotiabank cut […] ....

United States , Sanfordc Bernstein , Oene Mark Van , Davidw Meline , Pacific Biosciences , California Company Profile , Comerica Bank , Securities Exchange Commission , California Inc , Kayne Anderson Rudnick Investment Management , Goldman Sachs Group , Fairfield Bush , Free Report , California Price , Get Free Report , Director David , Exchange Commission , Investors Weigh In On Pacific Biosciences , Financial Advisors , California Company , California Daily ,

Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $8.00 at Scotiabank

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price objective reduced by Scotiabank from $15.00 to $8.00 in a report published on Thursday, Benzinga reports. They currently have a sector outperform rating on the biotechnology company’s stock. Several other equities research analysts have also weighed in on PACB. Barclays reduced their target price […] ....

United States , Pacific Biosciences , Davidw Meline , Oene Mark Van , Envestnet Asset Management Inc , Goldman Sachs Group , Group Plc , Ambassador Advisors , Prudential Financial Inc , California Company Profile , California Inc , Free Report , California Price , Get Free Report , Director David , Funds Weigh In On Pacific Biosciences , Asset Management , General Group Plc , California Company , California Daily , Pacific Biosciences Of California , Nasdaq Pacb , Lower Price Target ,